5-28. -...
TRANSCRIPT
7.CL References
® AcartOrk, F., Altug, N., 200i. In-vitro and in-vivo evaluation of a matrix-
controlied broiDOcriptine mesilate-releasing vaginal ring. J. Phanri. Pharmacol. 53
(12), ! 72M726.
<» Agnihotri, S.A., Mallikariuna, N.N., Aniinabhavi, T.M., 2004, Rect;nt: advances on
chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release iOO,
5-28.
® Agnihotri, S.M., Vavia, P.R., 2009, Diclofeiuic- loaded biopolyrneric
nanosuspensions for ophthalmic application. Nanomedicine: N.B.M, 5, 90-S)5.
® Aitkcn, M., Berndt, E.R., Cutler, D.M., 2009, Prescription drug spending trends in
the United States: looking beyo;nd the turning point. Heaitli Aff (Millwood).
28(1), 151- 160.
® AJun, W., Yan, S., Li, G., Huili, L., 2009. Preparation of aspirin and probuco! in
combination loaded chitosari nanoparticles and in vitro release study. Carbohyd.
Polym. 75, 566-574.
» Akbuga, .f,, Durraaz, G., 1994. Preparation and evaluation of crosslinked chitosan
microspheres containing furose:mide. In t..]. Pliarrn. I l l , 217-222.
• Aktas, Y., Andrieux, K., Alonso, M.f., Calvo, P., Gursoy, RN., Couvreur,
P., Capan, Y,, 2005. Preparation and in vitro evaluation of chitosan nanoparticles
containing a caspase inhibitor. I n t . P h a r m . 298(2), 378-83.
® Alam, M.I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Abuja, A.,
Akbar,M., 2010. Strategy for effective brain drug delivery. Eur. J. Pharm.
Sci, 40(5), 385-403
® Al-Ghananeem, A.M., Saeed, H., Florence, R., Yokel, R.A., Malkawi, A.H.,
2010. Intranasal drug delivery o f didanosine-loaded chitosan nanoparticles for
brain targeting; an attractive route against infections caused by aids viruses. J.
Drug. Target. 18: 381-388.
« Ali J, Ali M, Baboota S., 2010. Potential of nanoparticulate drug delivery Systems
by intranasal administration. Curr. Pharm. Des, 1644- 1653.
C hap ter 7 .Refereiice.s
Dept of Pliarniacewtics - Page 178
© Alsarra, I.A., Hamed, A.Y., Mahroiis, GJvl., Magliraby, Robayan, A.A.,
Alanazi, F.K., 2009. Miicoadhesive polymeric hydrogels for nasal delivery of
Acyclovir. Drug. FJev. Ind. Pharm. 35, 352-362.
® Aoyama, S., Kase, i l , Borrelli, E., 2000. Rescue of locomotor inipainnent in
dopamine D2 recept;or-deficient mice by an adenosine A2a receptor antagonist. J
Neurosci. 20, 5848--52.
B Artursson. P., Lindmark, T., Davis, SS,, 1994. Effect o f chitosan on the
permeability of irionolayers of intestinal epithelial ceils (Caco-2). Pharm Res. 11,
1358 -^1361.
e Avadi, MR., Sadeghi, A.M.M, Moharnmadpour, N., Abedin, S., Atyabi, F.,
f3inarvand, R., M. Rafiee-Tehrani, IVL, 2010. Preparation and characterization of
insulin nanoparticles using chitosan and Arabic gurn Vv'ith ionic gelation method,
Nanomed: Nanotech. Bioi. Med. 6, 58--63
® Babbar, A.K., Singh, K., Goef H.C., Chauha.n, U.S, Sharma, R.K., 2000.
Evaluation of 99mTc labeled Photosan-3, a heamatoporphyrin derivatii^e, as a
potential radiopharmaceutical for tumor scintigraphy. Nucl. Med. Biol. 27, 419-
426.
® Berger, J., Reist, M., Mayer, J.M., Felt, O., Peppas, N.A., Gurny, R., 2004,
Structure and interactions in covalently and ionically crtxsslinked chitosan
hydrogels for biomedical applications, Eur. J. Pharrn. Biopharm. 57, 19-34.
® Berthold, A., Cremer, K., Kreuter. .F., 1996. Preparation and characterization of
chitosan microspheres as drug carrier for prednisolone sodiinn phosphate a.s
model for anti-inflammatory drugs. J. Control. Rel. 39 (1), 17-25.
® Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-osuna, M., Panov, A.V.,
Greenamyre, .I.T., 2000. Chronic systemic pesticide exposure reproduces features
o f Parkinson’s disease. Nat, Neurosci. 3, i301-1306.
« Boonsongrit, Y., Mitrevej, A., Mueller, B.W., 2006. Chitosan drug binding
by ionic interaction, Eur .1 Pharm. Biopharm, 62(3), 267-74.
® Boonsongrit, Y., Mueller, B.W., Mitrevej, A., 2008, Characterization of drug-
chitosan interaction by IH NMR, FTIR and isothermal titration calorimetry. Eur.
J. Pharm. Biopharm. 69(3), 388-395.
Qtuipter 7___ _______ ___ __ __ References
Dept of Pharmaceutics Page 179
C hap ter 7 .References
Borlongan, C. V., Emerich, D.l-'., 2()03. Facilitation of drug entry into the CNS via
transient permeation of blood-brain barrier; laboratory aivd preiimiiiiir)'' clinical
evidence from bradykinin receptor agonist. Cerefjort, 13rain Res. Bull. 60, 297-
306.
Calvo, P., Goiiritin, B., Chacun, M,, 2001. Long-circulating PEGylated
polycyanoacry!al:c nanoparticles a.s new drug carrier for brain delivery. Pharm.
Res. 18, I ] 57-1166.
Calvo, P., Reinunan-Lopez, C., Vila-Jnta J.L,, Alonso, M.J,, 1997, Chitosan and
chitosan: ethylene oxide-propylene oxide block copolymer NPs as novel carriers
for proteins and vaccines, Phrani. Res. 14, i431--143<).
Campbell, M., Ozaki, IVI., Humphries, P., 2010. Systemic delivery of therapeirtic,s
to neuronal tissues; a barrier modulation approach. Expert. Opin. Drug. Deiiv. 7,
859-869.
Cai-vey, P.M., Ptak, L.R., Lin, D., Lo, E.S., Buhrfiend, C.M., Drucker, G.E.,
Fields, J.Z., 1993. Alterations in striatal neurotrophic activity induced by
dopaminergic drugs. Pharmacol Biochem Behav. 46 (1), 195-204.
Chang, W.H, Kao, C.H., Lin, C .I, Wang, S.J., 2007. Thermosensitive
nanostructure for hyperthermia treatment. US 20070154397.
Charlton, S., .fones, N.S., Davis, S.S., Ilium, L., 2007. Distribution and clearance
of bioadhesive formulations from the olfactory region in man; Effect of polymer
type and nasal delivery device. Eur. .1. Pharm. Sci. 30, 295-302.
Chen, L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W.,
Elastings, T.G., Kang, U.J., Zhuang, X., 2008. Unregulated cytosolic dopamine
causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28
(2), 425-433.
Chen, Y., Mohanraj, V..I, Wang, F., Benson, H.A., 2008. Desigining chitosan
dextran sulphate nanoparticles using charge ratio. AAPS Pharmscitech. S (4), 98-
105.
Chen, Y., Siddhalingappa, B, Chan PH., Benson, PLA., 2008. Development of
a chitosan-based nanoparticle formulation for delivery of a hydrophilic
hexapeptide, dalargin. Biopolymers. 90 (5), 663-670.
Bept of Pharmaceutics Page 180
» ChengLiang, L., Youlong, T., Chengslieng, L., Xiguang, C., Lejun, Y. 2()06.
Preparation, Cliaracterizatioii and application of cliitosan l:>ascd nanopaiticles. .1.
Ocean. Univcr. China, 6 (3), 237-243.
® C'henite, A., Busclirnann, M,, Wang, I),, Cliaput, C., Kandani N„ 2()01.
Rheological characterisation o f thennogelling chitosan/glyceroi-phosphate
solutions. Carboliyd. Polym. 46, 39-47.
ClH), K„ Wang, X., Nie, S., Chen, Z„ Shin, D.M., 2008. Tlierapeutic
nanoparticles for drug delivery in cancer. Ciiii. Cancer. Res, 14, 1310--13I6,
® Choi, Y., Sec, M., Kim, i , Lee, Y., 1997. High-performance liquid
chromatographic assay of bromocriptine in phisma and eye tissue o f the rabbit. .!.
Ciironiatography B. 694, 615-620.
0 Coi'bo, D.C., 1990. Characterization of the barrier properties o f mucosal
membranes. J, Pharm. Sci. 79, 202-206.
e Costantino, H.R., rilum, L„ Brandt, (}., Johnson, P.H., Quay, S.C., 2007.
Intrauasal delivery; Physicochemical and therapeutic aspects. Int. .1. Piianri. 337,
1-24.
o Crocker, A.D., Hemsley, K.M., 2001. An animal model of extrapyramidai side
effects induced by antipsychotic drugs: relationship with 132 dopamine receptor
occupancy. Prog Neuropsychopharmacoi Biol Psychiatry, 25, 573-590.
® Dahlin, M., Bjork, E., 2000. Nasal absorption of (S)-UH-301 and its transport into
the cerebrospinal fluid of rats. Int. J. Pharm. 195, 197-205.
® Dash, M., Chieliini, F., Ottenbrite, R.M., Chiellini, E., 2011. Chitosan~A versatile
semi-synthetic polyrtier in biomedical applications. Prog. Polym. Sci. 36, 981-
1014.
® De Campos, A. M., Sanchez, A., & Alonso, M. .1., 2001. Chitosan nanoparticles:
A new vehicle for the improvement of the delivery o f drugs to the ocular surface.
Application to cyclosporin A. Int. J. Phami. 224(1-2), 159-168.
® De Rosa, R., Garcia, A. A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N.,
Cattaneo, A., 2005, Intranasal administration o f nerve growth factor (NGF)
rescues recognition memory deficits in ADI 1 anti- NGF transgenic mice. Proc.
Natl. Acad. Sci,, 102 (10), 3811-3816,
C hapter 7 lleferences
Dept of Pharmaceutics Page 181
© De Souza Silva M.A., Mattern, C., "ropic B, {luston, J.P., 2009. Dopainiiiergic and
serotonergic activity in neostriatum and nucleus accumbens enhanced by
intraiiasai administration of testosterone Eur Neuropsychophannacol, I 9, 53'-63.
e De Souza Silva M.A., Topic B, Huston, J.P., Mattern, C., .2008. Iritranasai
administration of progesterone increases dopaminergic activity in amygdala and
neostriatum of male rats. Neuroscience. 157 (1), 196-203.
® Degim, IT ., Acartiirk, F., Eirdogan, D., Lortlar, N.D., 2003. Transderma!
Administration of Bromocriptine. Ijio!. Phann. Bul l. 26(4), 501— .50.5.
o Desai, N.P., Soon-Shiong, P., Yang, A., 2007. Novel formulatioiis of
pharmacological agents, methods for the preparation thereof and methods for tiie
use thereof US2007009256.3.
s Devika, R.B., Varsha, B.P., 2006. Studies on Effect of pH on Cross-liiikirigj of
chitosan with Sodium Ti-ipolypliospliate; A Tecliiiical Note. AAPS Pharm. Sci.
Tech. 7 (2), 50-57.
© Dhanda, D., Frey, W.H., Leopold, D., Kompella, U.B., 2005. Nose-to-brain
delivery: approaches for drug deposition in the human olfactory epithelium. Drug
Delivery Technol, 4, 64-72.
e Dhuria, S.V., Hanson, L.R., Frey, W.H., 2010. Intranasa! delivery to the central
nervous system; Mechanism and experimental considerations. J. Pharm. Sci.
99(4), I654-1673.
e Dodane,V., Khan, M.A., Merwin, J.R., 1999. Effect o f chitosan on epithelial
permeability and structure. Int. J. Pharm. 182, 21 -32.
• Dorsey, E.R, Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G.,
Kieburtz, K., 2007. Projected nmnber of people with Parkinson disease in the
most populous nations, 2005 through 2030. Neurology. 68(5), 384-386.
• Drewe, J., Keck, M., Guitard, P., Pellet, A., Johnston, B., Beglinger, C., 1991.
Relevance of pH dependency on in vitro release of bromocriptine from a
modified-release formulation. J. Pharm. Sci. 80 (2), 160-163.
® Dudhani, A.R., Kosaraju, S.L., 2010. Bioadhesive chitosan NPs: Preparation and
characterization. Carbohyd. Polym. 81, 243-251,
C hapter 7 References
Bept of Pharmaceutics Page 182
® Dung, T.H., Lee, S.R., Han, S.D., Kim, S.J., Jii, Yi/L, K.im, K4.S., Yoo, M., 2007.
Chitosati- TPP nanopartick as a release system of antisense oligonucleotide in tlie
oral environment. J. Nanosci. Nariotecli. 7 (! 1), 3695-3699.
® Esposito, E Fantin, M., Marti, M., Drechsicr, M., Paccaniiccio, L., Mariani, P.,
2008. Solid iipicl iianoparticlcs a.s delivery systeriis for bromocriptine. Pharm. Res.
25 (7) 1521-1530.
® Esposito, E., Cortesi, R., Nastmzzi, C., 1996. Gelatin microspheres: influence of
preparation parameters and thermal treatment on chcmico-pliysical and
biopharniaceutical properties. Bioinater. 17 (20), 2009-2020.
9 Esposito, E., Mariani, P., Ravaiii, L., Contado, C., Voita, M., Bido, .S., Drechsler,
M., Mazzoni, S., Menegatti, E., Morari, M., Cortesi, R., 2012. Manoparticiiiate
lipid dispersions for bromocriptine delivery: Characterization and in vivo study.
Eur. J. Pharm. Biopharrn. 80 (2), 306-314.
• Esumi, K., Takei, N., & Yo,shimura, T., 2003. Antioxidant-potentiality of
goldchitosan nanocomposites. Colloids Surf Ei; Bioint. 32, 117-123.
® Fan, W., Yan W,, Xu, Z., Ni, FI. 2012. Formation mechanism of monodisperse,
low molecular weight chitosan naiioparticles by ionic gelation technique.
Colloids. SurfB. 90,21-27.
8 Fazil, M., Md, S., Haque, S., Sahni, J.K., Baboota, S., Ali, .1., 2012. Development
and Evaluation of Rivastigmine loaded Chitosan Nanopaiticles for Brain
Targeting. Eur. J. Pharm. Sci. 47: 6-15.
® Fernandez, M., Negro, S., Slowing, K., Fernandez-Carballido, A., Barcia, E.,
2011. An effective novel delivery strategy of rasagiline for Parkinson’s disease.
Int. J. Pharm. 419, 27F - 280.
® Fernandez, M..FA., Renninan Lopez, C., Cuna Vilan, M.M., Alonso Sande, M.,
2006. Nanoparticles for the administration of active ingredients, method of
producing said particles and composition containing same. US20060134785.
0 Fernandez-Urrusuno, R., Romani, D., Calvo, P., 1999. IDevelopment of a freeze
dried fonnidadon of insulin-loaded chitosan nanoparticles intended for nasal
administration, STP, Pharm. Sci. 5, 429-436.
Cluiipter 7 IRefereiices
Dept of Pliarmaceutlcs Page 183
e Florence, K., Maiiisha, L., Kuiriar, B.A.,Ankirr, K., K'umar,
M.A., Ambikanandan, M., 201 L intranasai clobazarn delivery in the treatrnent of
status epilepticus. J. Pharm. Sci. 100(2), 692-703.
» Fuciitc-Fernandez, R„ Schulzer, M., Mak, 11., Sossi, V., 2010. Trials of
neiiroprotcctive therapies ibr Parkinson's disease: problems and limitations,
Parkinsonism llelat. Disord. 16, 365 -369.
® Gan, ()., and Wang, T., 2007. Chitosan rsanoj3article as protein delivery carrier -
Systematic examination of fabrication conditions for efficient loading and release.
Coll. and Surface B: EJioint. 59, 24-34.
Gan, Q., Wang, T., Cochrane, C., & McCarron, P. 2005. Modulation of surface
charge, particle size and rnorphologica! properties of chitosan-TPP rianoparticles
intended for gene delivery. Colloids Surf, B: Bioint. 44(2-3), 65-73.
Gao, X., Chen, J., Tao, W., Zhu, J,, Zhang, Q., Chen, H., Jiang, X., 2007. UEA I-
bearing nanoparticles for brain delivery following intranasa! administration. Ii t. J.
Pharm. 340, 207-215.
• Gavini, E., Rassu, G., Sanna, V., Cossu, M., Giunchedi, P., 2005. Mucoadhesive
microspheres for nasal administration of an antiemetic drug, metoclopramide; in
\ntro/ex-vivo studies. J. Pharma. Pharmacol. 57, 287-294
« Go, C.L., Rosales, R.L., Schmidt, P, Lyoiis, K .fi, Pahvva, R., Okun., M.S., 2011.
Generic versus branded pharmacotherapy in Parkinson’s disease; Does it matter?
A review. Parkinsonism Relat. Disord. 17 (5), 308-312.
e Gozes, I , Eliezer, G., .foanna, M. H., Efrat, D., Conor, M.S., 2004.Vasoactive
Intestinal Peptide (VEP) Regukites Activity-Dependent Neuroprotective Protein
(ADNP) Expres.sion In Vivo. J. Mol. Nenrosci. 33(3), 278-283.
® Graff, C.L, Zhao, R., Pollack, G.M., 2005a. Pharmacokinetics of substrate uptake
and distribution in murine brain after nasa! instillation. Phami. Res. 22, 235-244.
• Graff, C.L., Pollack, G.M., 2004. Drug transport at the blood-brain barrier and
the choroid plexus. Curr. Drug. Metab. 5, 95-108.
• Graffl, L.C., Pollock, G.M., 2005b. Nasal drug administration: potential for
targeted central nervous system delivery. J Pharm. Sci. 94, i 187-1195.
CiiaptciT 7 Ftefcreiices
Dept of Pharmaceutics Page 184
Graiiveau-Renouf, S., Valente, D., Durocher, A., Grognei:, J.M., Ezaii, B., 2000.
Microdialysis study of bromocriptine and its inctaboiites in rat pituitary and
striatum. Eur. J. Drug. Metab. Pharmacokinet. 25: 79-84.
Hans, M.I,.., Lowman, A.M., 2002. Biodegradable ]MPs for drug delivery and
targeting. Curr. Opin. Solid State Mater. Sci. 6 (4), 319-327.
Hanson, L., Roeytenberg, A., Martinez, P.M., Coppes, V.Cl, Sweet, D.C., Rao,
R.J., Marti, D.L,, Hoekman, .I.D., Matthews, R.B., Frey, W.H., Panter, S.S., 2009.
Intrana.sa! deferoxamine provides increased brain exposure and significant
protection in rat isciiemic stroke. J. Pharmacol. Eixp, Tlicr.330, 679-^i6.
Haque, S., M’d, S., P’azil, IVl., Sahni, J.K., Ali, J., Baboota, S., 2012,
Nanomedicines for Brain Targeting: A Patent Review. Reccnt Patent on
Nanomedicines, !(2), 149-161.
Haque, S., Md, S., Fazil, M., Sahni, J.K., Baboota, S., Dang, S., Ali, J,, 2011.
Role of Chitosan Biomaterials in Drug Delivery Systems; A Patent Perspective.
Recent. Pat. Mater. Sci. 4 (3), M 5.
Idaque, S.,Md, S., Alam, I., Sahni, J.K., Ali, J., Baboota, S., 2012. Nano-structure
based drug delivery systems for brain targeting. Drug. Dev. hid. Phann. 38(4),
387-411.
Hu, B„ Pan, C., Sun, Y., Hou, Z., Ye, 11., & Zeng, X. 2008. Optimization of
fabrication parameters to produce chitosan-tripolyphosphatc nanoparticles for
delivery of tea catechins. J. Agri. Food. Chem. 56(16), 7451-7458.
Hu, Y., Jiang, X., Ding, Y., Ge, H., Yuan, Y., Yang, C., 2002. Syndiesis and
characterization of chitosan-poly(acryl!C acid) nanoparticles. Biomaterials.
23(15), 3193 ^ 3201.
Huang, C.H., Kimura, R., Nassar, R.B., Hussain, A., 1985. Mechanism of nasal
absorption of drugs ;Physicochemical parameters influencing the rate of in situ
nasal absorption of drugs in rats. J. Pharm. Sci. 74,608-611.
Huang, Y., Yeh, M., Chiang, C., 2002. Formulation factors in preparing BTM-
chitosan microspheres by spray drying method. Int. J. Pharm. 242, 239-242.
ICFI harmonised tripartite guideline, 2003. Stability testing of New Drug
C hapter 7 References
Dept of Pharmaceutics Page 185
Substances and Products ()1 A(R2). ICH harmonised tripartite guideline
® ICH harmonised tripartite guideline, 2005. Validation o f analytical procedures:
text and methodology Q2(RI). ICH harmonised tripartite guideline
® Ilium, L., l998.Chitosan and its use as a pharmaceutical excipient, Pharrn. Res.
15, 1326-1331.
® niurn, L., 20()0. Transport of drug from the nasal cavity to the ceivtral nervous
system. Pharni. J. Sci. 11, 1-18.
» Ilium, L , 2004. Is nosc-to-brain transport o f drugs in man a reality? J. Pharni.
Pharmacol. 56, 3--17.
® Ilium, L., Farraj, N.l-'., Davis, S.S., 1994,Chif:osan as a novel na.sal delivery system
for peptide drug.s, Phariii. Res. 11,1186-1189.
® .fackson, J.V., Moss, M.S., Widdop, B., 2005. Clark analytical and toxicologica!
data: in Mojfet, A.C. (Eds). Monograph of bromocriptine mesylate, The
Pharmaceutical Press, London, PP. 401-402.
9 Jia, X., Chen, X., Xu, Y., Han, X., Xu, Z., 2009. Tracing transport of cliitosan
nanoparticles and molecules in Caco~2 ceils by fluorescent labeling. Cabohyd.
Polym. 78, 323-329.
9 Jin, K., Xie, L., Childs, .1., 2000. Cerebral neurogenesis is induced by intranasal
administration o f growth factors. Ann Neurol 5, 405-409.
» Jingou, J., Shilei, H., Weiqi, L., Danjun, W., Tengfei, W., Yi, X. 2011.
Preparation, characterization o f hydrophilic and hydrophobic drug in combine
loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids
Surf B. 83, 103-^107.
« Jung, J., Perrut, M., 2001. Particle design using supercritical fluids: Literature and
patent survey. J. Supercritical Fluids. 20, 179-219.
• Junginger., H.E., 1997. Mucoadhesive polymers in peroral peptide drug delivery
polycarbophil and chitosan arc potent enhancers of peptide transport across
intestinal mucosa in vitro. J. Control. Release. 45, 15-23.
• Kaloti, M., Bohidar, M.B., 2010. Kinetics of coacervation transition versus
nanoparticle formation in Cliitosan-TPF solutions. Colloids. Surf B. Bioint. 81,
165-473.
C hap ter 7 K.t;fererices
Dept of Pliarinaceutics P«ge 186
» Kao, H.D., Traboulsi, A.,, Itoh, S., Dittert, L., Hussain, A., 2000. Enhancement of
the systejnic and CNS specific delivery of L-dopa by the nasal administration of
its water soluble prodrugs. Phann. Res. 17, 978-984.
e Katdare A., Chaiibal M.V., 2006. Excipient Development for Ptiarrnaueutical
Biotechnology and Drug Delivery Systems. Taylor & I^raacis Grou}:), LLC, USA.
© IChaii, S., K., Bobade, N., Yeole, P., Gaikwad, R., 2010. Formulation of
irvtranasa! rniicoadhesive temperature-mediated in siiii gel containing ropinirole
and evaluation of brain targeting efliciency in rats. .1. Drug. Target. 18, 223-234.
e Korscmeyer, RAV., Giirny, R., Docler, E,, Bur, P., Pej3pas, M.A., 198.3.
Mechanism of solute release from porous hydropliilic polymer, hrt. J. F^harm. 15,
25-35.
e Kraig, R.P, Kaminski, M., 2008. Compositions and method for brain specific
targeted delivery of therapeutic agents. US 20080274202 Al.
e Kreuter, .f., Alyautdin, R.N., Karkevich, D.A., Sabel, B.A., 2000. Drug targeting
to the nervous system by nanoparticles. US 6117454.
8 Kreuter, J., Gelperina, S., Maksimenko, ()., Khalanskiy, A., 2009. Polylaetide
Nanoparticles. US 20090263491 A l.
• Kreuter, J., Nanoparticles, in; Swarbrick, J. Boylan, .f.C. (Eds.), Encyclopedia of
Pharmaceutical Technology, 10, 1994, pp. 165-190.
e Kumar, M., Misra, A., Mishra, A.K., Mishra, P., Pathak, K., 2008a.
Miieoadhesive nanoeniulsion-based intranasal drug delivery system of olanzapine
for brain targeting. J. Drug Target, 16(10), 806-814.
• Kumar, M., Misra, A., Babbar, A.K., Mishra, A.K., Mishra, P., Pathak, K., 2008b
Intranasal nanoemulsion based brain targeting ding delivery system of
risperidone. Int. .1. Pharm. 358, 285-91.
• Kvermo, T., Hartter, S., Burger, E., 2006, A review of the receptor binding and
pharmacokinetic properties of dopamine agonists Clin. Ther. 28:1065-1078.
• Kwon, H.Y., Lee, J.Y., Choi, S.W., Jang, ¥ ., Kim, J.H., 2001. Preparation of
PLGA nanoparticles containing estrogen by emuisification-diffusion method.
Colloids Surf. A: Physicochem. Eng. Aspects. 182, 123-130.
C hapter 7 R.eferences
Dept of Pharmaceutics Page 187
® L a b h a sc tw a r , V .D , R eddy, M.K.,, 20(56. M e th o d and c o m p o s i t io n for in h ib i t in g
rei3erfusion in ju ry in the bratii. US 20060067925 A I .
© Lai, B.C.L., Tsui, J.K.C., 2001. Epidemiology of Parkinson’s disease. British.
Col. Med. J. 43, 133-137
® Leong, K..W., Haller, M.F., Maiavaud, B.A., Lc Visage, C.S., 2004. Systejnic
delivery of compounds through non-invasive bladder administration. US6797704.
Li, Y.P., Pei, Y.Y., Zhou, Z.H., Zluing, X.Y., Gu, Z.f!., Ding, .1, Zhou, J.J., Gao.
X.J., 2001. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-
[alpha] carrier.^. J. Control. Release. 71, 287-296.
Liin, J.H., Kim, S.S., Boo, D.¥L, N o j l , Kang, B.Y., Kim, E.M., Hwang, O,,
Choi, 2009. Protective effect of bromocriptine against BH4-induced Cath.a
cell death involving up-regulation o f antioxidant enzymes. NeiirosGi. Lett. 451,
185-489.
® Lin, X., Zhai, G., Sarad, M., Lohstroh, P.M., 2009. Telomera.se delivery by
biodegradable Nanoparticie. US 20090142408 A l.
• Lins Dantas, P.M., 2011. Pharmaceutical compositions of naiioparticles
containing active ingredients. US20110118364.
® Liu, FL, & Gao, C., 2009. Preparations and properties of ionically crosslinked
chitosan nanoparticles. Polym. Adv. Tech. 20, 613-619.
» Liu, H., Chang, Y., 2001. Preparation and properties o f ionically cross-linked
chitosan nanoparticles. Polym. Adv. Technol. 20 (7), 613-619.
® Liversidge, G., Jenkins, S., Liversidge, E.M., 2011. Injectable nanoparticulate
olanzapine formulations. US7910577.
• Lockman, P. R., Joanna, M. R., Mumper, J. D., Allen, D,, 2004. Nanoparticie
Surface Charges Alter BloocL-Brain Barrier Integrity and Permeability. J. Drug.
Target. 12,635-641.
® Lowary, O.H., Rosebrough, N.J, Farr, A.L., 1951. Protein measurement with the
Folin phenol reagent. J. Biol. Chem. 193, 265--275.
® LueBen, H.L., de Leeuw, B.J., Laogemeyer, M.W., 1997. Mucoadhesive polymers
in peroral peptide drug deliveiy. IV. Polycarbophil and chitosan are potent
C hap ter 7 References
Dept of Pliarm aceutks Page 188
C!liapl:cr 7 Refererices
enhancers of peptide transport across intestinal nnicosac in vitro. J. Control.
Release. 45, 15-23,
® Luo, Y., Zhang, B., Cheng, W.l!., Wang, Q,, 201.0. Preparation, chai’acterization
and evaluation of selenite-loaded chitosan/T'PP naiioparticles witii or vvitliout zein
coating. Carbohyd Polyiii 82, 942-95 L
© Luthra, P.M., Barodia, S.1C., Raghubir, R,, 2009. Antagonism o f haloperidol-
induced swim impairment in 1-dopa and caffeine treated mice: A pre-elinical
model to study Parkinson’s disease, i. Neurosci. Methods. 178, 284-290.
© MacICay, J.A., Deen, .13.F., Szoka, .f.R., Francis, C., 2005. Distribution in brairj of
liposomes after convection enhanetid delivery; modulation by particle charge,
particle diameter, and presence o f steric coating. Brain Research. 1035, 139-153.
® Malodia, 1C., Singh, S.K., Mishra, D.N., Shrivastave, B., 2012. Nanoparticles: An
advance technique for drug delivery. Res. J. Pliarm. Bio. Chem. Sci. 3 (3), 1186-
1208.
Mao, H.Q., .Roy, .K., Troung~Le, V.L., Janes, K.A., Lin, K.Y., Wang, ¥ ., August,
J.T., Leong, K.W., 2001. Chitosaii-DN,A nanoparticles as gene carriers;
synthesis, characterization and transfection efficiency. .1. Control. Relea.se. 70,
399-421.
® Mao, S., Chen, J., Wei, Z., ..Lin 11., Bi, D., 2004. Intranasal administration of
melatonin starch microspheres. Int. J. Pharm. 272, 37-43.
• Md, S., Ahuja, A., Khar, R.K., Baboota, S., Chiittani, K., Mishra, A.K., Ali, J.,
201L Gastroretentive drug delivery system of acyclovir-loaded alginate
mucoadhesive microspheres: Formulation and evaluation. Drug. Deliv. 18 (4)
255-264.
e Md, s., Haqiie, S., Sahni, J.K., Baboota, S Ali, J., 2011. New non-oral drug
delivery systems for Parkinson’s disease treatment. Exp. (3pin. Drug. Deliv.
8(3):359-74.
® Md, S., Kiimar, M., Baboota, S., Sahni, J.K., Ali, J., 2012. Preparation,
Characterization and Evaluation o f Bromocriptine Loaded Chitosan .Nanoparticles
for Intranasal Delivery. Sci. Adv. Mater. 4 (9), 949-960.
Dept of Pliarinaceiitics Page .189
C hap ter References
Mi, F., Shyu, S., Lee, S., & Wong, T., 1999. K in e t ic s tu d y o f chitosan-
tripolyphosphate complex reaction and acid-resistivc p ro p e r t ie s o f the c li i tosa ii..
t r ip o ly p h o sp h a te gel bead s p re p a re d by in - l iq u id cu r in g m e th o d . J. P o ly in Sci. B:
Polyrn Physics. ,37(14), 1 5 5 1 -1 5 6 4 .
Mirkin, C.A., L e ts in g c r , R.L., IVIucic, R .C ., S torlioff , J .J . , Elghaiiian, R., Taton,
T .A ., 2007 . N a n o p a r t ic lc s h a v in g o l ig o n u c le o t id e s a t tac l ied th e re to a n d uses
t h e re ! V) rc . U S 72 5 92 5 2.
M is try , A., S toh iik , S ., I l ium , L., 20 0 9 . N a n o p a r t ic le s Ibr d i re c t n ose - to -b ra ii i
d e l iv e ry o f d rugs, hit. J. P h a n n . 379 , 146-157 .
M itra , S., G aur , U., G h o sh , F’.C., M aitra , A .N . , 2001 .T in i io r ta rg e te d d e l iv e ry o f
encapsulated dextran-doxorubicin conjugate using ch i to sa i i nanoparticles as
carrier . .1. C ontro l. R e lease . 74, 3 i 7 - 3 2 3 .
M itta l , D ., All, A ., M d , S., B a b o o ta , S ., S ah n i , J.K,., A li , J . , 20 1 3 . in s ig h ts in to
Direct nose to brain delivery: Current s ta tus an d ftiture p e r s p e c t iv e . D ru g Deliv.
(In P ress) .
Moffat, A.C., Osselton,M.D., Widdop, B., 2005. Clarice analysis of drugs and
poisons. B"'' Edidon
Morris, G.A., Castile, J., Smith, A., Adams, G.G., Harding, S.E, 2011.The effect
of prolonged storage at different temperatures on the particle size distribution of
tripolyphosphate (TPP)-chitosan nanoparticles. Carbohydr. Polym. 84, 1430-
1434.
Motvi/ani, S.K., Chopra, S., Talegaonkar, S., Kohii, K,, Ahmed, F.Z., Khar, R.K.,
2008. Chitosan-sodium alginate nanoparticles as submieroscopic reservoirs for
ocular delivery: Fornuilation, Opdinization and w vitro characterization. Eur. j.
Pharm. Biopharra. 68, (3), 513-525.
Miiller, R.H. Colloidal Carriers for Controlled Drug Delivery and Targeting. CRC
Press, Boca Raton; 1991 pp. 45-56.
Muller, RH., Jacobs, C., Kayser, O., 2001. Nanosuspensions as
particulate drug formulations in therapy; Rationale for development and what we
can expect for the future. Adv. Drug. Deliv. Rev. 47, 3-19
Dept of Pharmaceutics Page 190
C hap te r 7 References
Muthane, U.B., Ragothaman, M., Guru raj, (1, 2()07. Epidemiology of Parkinson’s
Disease and Movement Disorders in India; Problems and Possibilities. JAPI. 55,
719-724,
Nagavarma, Yadav, H.K.S., Ayaz, A., Vasudha, L.S., ShivakuiTiar, H.G.,
2012. Different Techniques for preparation of polyrricric nanop;irticles- A
Review. Asian. J. Pharrn. Clin. Res. 5 (3), 16-23.
Nashatizadch, M.M., Lyons, K.Ei., Pahwa, R., 2009. A review of ropiriirolc
proioDged release in i^arkinson’s disease. Clin. Iirterven. Aging. 4, 1,79 -186.
Newrnan, S.P., Wilding, f.R., 1998. Gamrna scintigraphy; an in vivo technique
for assessing the equivalence of inhaled products, int. J. Pharm. 170., 1-9.
Nicolaas, G. M. S., Susanne, O., .lanet, A. FL, Albertus, (}.deBoer., Kjcll,
M.V., Artursson, P., 1997. Chitosans as Absorption Enhancers for Pooriy
Absorbable Drugs 2: Mcchanism of Absorption Enhancement. Pharm. Res. 14
(7), 923-929.
Nicolescu, C., Arama, C., Nedelcu, A., Monciu, C.M., 2010. Phase solubility
studies of the inclusion complexes of repaglinide with p-cyc!odextrin and f]-
cyclodextrin derivatives. E'annacia. 58 (5), 620-628.
Niwa, T., Takeuchi, H., F!ino, T., Kimou, N., Kawashima, Y., 1993. Prepararion of
biodegradable nanoparticles of water-soluble and insoluble drugs vvith D, L-
iactide/ glycolide copolymer by a novel spontaneous eniulsification solvent
diffusion method, and die drug release behavior. .1. Control. Release. 25, 89-98.
Noyes, K., Liu, H, Li, Y., Holloway, R., Dick A.W., 2006. Economic burden
associated with Parkinson’s disease on eldedy medicare beneficiaries. Mov.
Disord. 21(3), 362-372.
Nutt, J.G, Wooten, G.F., 2005. Diagnosis and initial management of Parkinson’s
disease. N. Eng. J. Med. 353, 1021-1027.
Nyholm, D., 2006. Enteral levodopa/carbidopa gel infusion for the treatment of
motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev
Neurother. 6( 10): 1403-1411.
Dept of Pharmaceutics Page 191
® O’Brien, J.A, Ward, A., .Michels, S.L., Tzivclekis, S., I3raiidt, M.J., 2009.
Economic burden associated with Parkinson disease. Drag Benefit Trends. 21(6),
179-190.
® Ohkawa, H., Ohisiri, N., Yagi, K., 1979. Assay for lipid peroxides in animal
tissues by thiobarbituric acid reaction. Anal. Biochcm. 95, 359-364.
s Pan, Y., Li, Y., Zhao, H., Zheng, J., Xu, IL, Wei, G„ 2002. Bioadhesive
polysaccharide in protein delivery system: Cliitosan nanoparticles improve tlie
intestinal absorption o f insulin in vivo. Int. J. Pharm, 249(1-2), 139..147,
© Papadirnitriou, S., Bikiaris, D., Avgoustakis, K., Karavas, E'., Georgarakis, M.,
2008. Ghitosan nanoparticles loaded with dorzolarnide and pramipexole.,
Carbolnyd Polym 73, 44--54.
» Pardridge, W.M., 1991, Peptide Drug Delivery to the }3rain. Raven Press, New
York, pp. 99--122.
» Pardridge, W,M,, 1999. Blood brain barrier biology and methodology, .1
Neurovirol. 5, 5556-5569.
e Park, U.S., Lee, .I.Y., Cho, S.H., Back, Lee, S.J., 2002. Colon delivery of
prednisolone based on chitosan coated polysaccharide tablets. Arch. Pharm. Res.
25:964-968.
® Pires, A., Fortuna, A., Alves, G., Falcao, A,, 2009. Intranasal Drug Deliveiy:
How, Why and What for? J. Pharm. Sci. 12 (3), 288 3 H .
® Prokop, A. 2004. Micro-particulate and nano-particulate polymeric delivery
sy.stem US20046726934.
9 Prokop, A., 2003. Drug delivery system exhibiting permeability control
US20036589563.
® Pujara, C.P., Shao, Z., Duncan, M.R., Mitra A.K., 1995. Effects of formulation
variable.s on nasal epithelial cell integrity: Biochemical evaluations, Int. J, Phcirm.
114,197-203
® Qi, L., Xu, Z-, .fiang, X., Hu, C., Zou, X., 2004. Preparation and antibacterial
activity of chitosan nanoparticles. Carbohyd. Res. 339, 2693-2700.
C hapter 7 References
Dept of Pharmaceutics Page 192
® RaoJ,P., GcckeJer, K.E., 201!. Polymer nanoparticlcs: f^reparatioii techniques
and size control parameters, Prog. Poiym. Sci. 36 (7), 887-913.
• Reddy, J.R. 2010, Preventive anti therapeutic vaccinc for A!:zheimer’s disease. US
20(00!73004.
® Reddy, L , Sharma, R.., Chuttani, K., Mislira, A., Murthy, R., 2004. Etoposide-
incorporated tripahnitin narioparticles witii different surface charge: fomrulation,
characterization, radiolabcling, and biodistribution Studies. AAPS J 6(3), 23.
® Reddy, R.G., Erathodiyil, N„ 2005. Degradable nanoparticles. US20050I 96343,
e Reis, C.P., Neufekl, R.J., Ribciro, A.J., Veiga, F., 2006. Nanoencapsulation I.
Methods for preparation of drug-loaded polymeric nanoparticles Nanomed:
Manotech, Bio, and Med. 2, 8~ 2 1.
e Reger, M.A., Watson, G.S., Frey, W.H., 2006. Effects of intranasal insulin on
cognition in memory-impaired older adults: modulation by APOE genotype.
Neurobiol Aging. 27, 451-458.
9 Reverchon, E., Adami, R., 2006. Nanoniaterials and superci'itica! fluids. J.
Supercritical Fluids. 37, 1-22.
® Riggs, J. E., 2001. Age specific rate of neurological disease. Neurobio] Aging. 1:3-
n
® Ringe, K., Radunz, H.E., Kubasch, .1., 2009. Nanoparticles Designed for Drug
Delivery. US 20090297613 AL
» Rolland, .I.P., Maynor, B.W., Euliss, L.E., Exner, A.E., Denison, G.M.,
DeSimone, J.M., 2005. Direct fabrication and harvesting of monodisperse, shape-
specific nanobiomateriais. J. Am. Chem. Soc. 127, 10096-10100.
® Saboktakin, M.R., Tabatabaee, R.M., Maharramov, A., Ramazanov, M.A., 2010.
Design and characterization o f chitosan nanoparticles as delivery systems for
paclita.x,el Carbohyd. Polym. 82, 466-471.
» Sadeghi, A., Dorkoosh, F.A., Avadi, M.A., Saadat, P Rafiee-Tehrani, M,,
Jiinginger, H.E., 2008. Preparation, characterization and antibacterial activities of
chitosan, N-trimethyl chitosan (TMC) and N~diet:hylmethyl chitosan (DEMC)
nanoparticlcs loaded v/ith insulin using both the ionotropic gelation and
polyelectrolyte complexation methods. Int. J. Pharm. 355, 299-306.
Cliapter 7 References
Dept of Pliarmsceutics Page 193
® Sakane, T., Akizuki, (V!,, Taki, Y., Yamasiiita, S ., Sezaki, H., Naclai, T., 1995.
Direct drug transport from the rat nasai cavity to the cerebrospinal fluid: the
relation to the molecular weight of drugs. J Pharrn Pliarmacol, 47 , 379-381.
® Sakane, T., Akizuki, M., Taki, Y., Yamasiiita, S., Se?:aki, H., Nadai, T., 1991. Tlie
transport o f a drug to the cerebrospinal fluid directly from the nasal cavity: the
relation to the lipophilicity of the drug. Cheni Pharm Bull. 39, 2456--245H.
e Sakane, T., Akizuki, M., Taki, Y., Yamasiiita, S., Sezaki, H., Nadai, T., 1994.
transport from tlie rat nasal cavity to tlic cercbrospina! fluid; the relation f:c> tlie
dissociation of the drug. .1. Pharm. Pharmacol. 46, 378-379.
® Salvador, A., Dubreuil, D., Denouef, J., Millerioux, L., 2005. Sensitive metliod for
the quantitative determination of brosnocriptine in human plasma by liquid
chromatography^^landem mass spectrometry. J. Chromatography. 13. 820, 237-242.
e Samson, G., de la Calera, A.G., Dupuis-G irod, S.,Faure, F., Decullier, E., 2011.
Ex vivo study of bevacizurnab transport through porcine nasal mucosa. Eiir. J.
Pharm. Biopharm. 80 (2), 465-469
9 Sarmento, B., Ferreira, D., Veig, P., Ribeiro, A., 2006. Characterization of insidin-
loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC
and FTIR studies. Carb Polym. 66, 1-7
® Schapira, A.Fl.V., 2005. Present and future drug treatment for Parkinson’s
disease. J. Neurol. Neurosurg. Psychiatry. 76, 1472-4478.
a Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein bound and nonprotein
sulftiydryl group in tissue u'ith Ellnian’s reagent. Anal. Biochern. 25,192-205.
® Segal, M.B., 2000. The choi’oid plexuses and the barriers between the blood and
the cerebrospinal fluid. Ceil Mol Neurobiol. 20, 183--196.
® Seju, U., Kumar, A., Sawant, K.K., 2011. Development and evaluation of
olanzapine-loaded PJXiA nanoparticles for uose-to-brain deliveiy: in vitro and in
vivo studies. Acta. Biomater. 7, 4169-4176.
• Shah, S., Pal, A., Kaushik, V.K., Devi. S., 2009. Preparation and characterization
of venlafaxine hydrochloride-loaded chitosan nanoparticles and in vitro release of
drug. Applied. Polym. Sci. 112, 2876-2887.
Clisipter 7 References
Dept of Pharmaceutics Page 194
e Shu, X.Z., Jhu, K.J., 2002. The itifliience of niultivalcnt |)hosphat:e structure on
the properties o f ioriicaHy cross-linked cliitosan filiiis for cootroiled drug release,
Eur. J. Pharm, Biopharrn,. 54, 235..243.
e Singh, N., Piliay, V., Choonara, Y.E., 2007. Advances in the treatment: of
Parkinson’s di.sease. Prog. NeurobioL 81, 29-44.
» Smith, E., Wood, M., Dornish., 2004. Effect of cliitosan on epithelial cell tight
junctions. Pharm. Res. 2 i, 43-49.
© Soane, R.J., Frier, M., Perkins, A.C., Jones, N.S., Davis, S.S., Illiini, L., 1999.
fZvaluation of the clearance characteristics of bioadhesive systems in huirians. Int.
.1. Phann. 178, 55-65.
® Soane, R..I., Hinchcliffe, M., Davis, S.S., Ilkrm, L., 2001. Clearance characteristics
of chitosan based formulations in the sheep nasal cavity, hit. I. Phann. 217, '183-
191.
® Spector, R., 2000. Drug transport in the rnammcilian central nervous system;
multiple complex systems. A critical analysis and commentaiy. Pharmacology.
60, 58-73.
® Sun, Y., Mezian, M., Pathak, P., Qu, L,, 2005. Polymeric nanoparticles from rapid
expansion of supercritical fluid solution. Chemistry. 11, 1366-1373.
e Sung, 11.W., Peng, S.F, Tu, H., 2011. Nanoparticles for protein drug delivery. US
7879312 BL
® Sung, H.W., Tu, H., 2011. Nanoparticles for protein drug delivery. US 7910086
Bl.
e Sung, H“W., Lin, Y., Chen, M., Tu, FL, 2009. Nanoparticles for monoclonal
antibody delivery, LJS7541028.
• Tang, E.S.K., M. Huang, M., Lim L.Y., 2003. liltrasonication of chitosan and
chitosan nanoparticles. Int. J. Pharm. 265:103-114.
e Tantishaiyakul, V., Kaenopparat, N., Ingkatavvoniwong, S., 1999. Properties of
solid dispersions of piroxicam in polyvinylpyrrolidone. Int. i. Pharm. 181: 143-
151.
Ciiaptei' 7 References
Dept of Pharmaceutics Fage 195
C Is ap te r 7 Re fe re n ces
Thanou, M., Verhoef, J.C., Juniginger, H.E., 2001. Orai drug absoiptioti
enhancement by chitosaii and its derivatives. Adv. Drug. Deliv. Rev. 52, 117-126.
Thorne, R.G., Proiik, J., Padmanabhan, V., 2004. Delivery o f insuiin-likc growth
factor to the rat brain and spinal cord along olfactory and trigeminal patlivvays
following intranasal administration. Neiirosciencx;. 127, 4 8 1-496.
Tokuinitsu, H., Ichikawa, Y., Fukumori., 1999. Chitosan-gadopeDtetic acid
complex nanoparticlcs for gadolinium neutron capture therapy o f cancer:
preparation by novel emidsion-droplet coalescence technique and characterization.
Pharm.Res, 16, 1830-1835.
Tou(on.se, A., Sufh'van, A.M., 2008. Progress in Ptu'kinson’s disease— Where do
we stand? Prog. Neurobioi. 8.5, 376“-'392.
Trapani, A., De Giglio, E., Cafagna, D., Den ora, N., Agrimi, G., Cassano, T.,
Gaetani, S., Cnomo, V., Trapani, G., 2011. Characterization and evaluation of
chitosan nanoparticlcs for dopamine brain delivery. Int. .1. Pharm. 419, 296- 307.
Trevitt, J., Vallance, C., Harris, A., Goode, T., 2009. Adeno.sine antagonists
reverse the cataleptic effects of haloperidol: Implications for the treatment of
Parkinson's disease. Pharmacol. Biocheni. Behav. 925, 21--527.
Tsai, Y.M., Chien, C.F., Lin, L.C., Tsai, T.H., 2011. Curcumin and its nano
formulation: The kinetics of tissue distribution atid blood-brain barrier
penetration. Int. J. Pharm. 416, 3 3 1- 33<S.
Turos, E., Cormier, R., Kyle, D.E., 2010. Polyaci7 late Nanoparticle Drug
Delivery. US 20100278920.
United State of Pharmacopoeia, 2006. United States Pharmacopoeia! Convention,
Rockville, USA.
Upadhyay, K.K., .Bhatt, AN., Castro, E., Mishra, AK., Chuttani, K.,
Dwarakanath, BS., Schatz, C., Le, Meins JF., Misra, A., Lecommandoux, S.,
2010. In vitro and In vivo evaluation of docetaxel loaded biodegradable
polymersomes. Macromol. Biosci. 10 (5), 503-512.
Vautier, S., Lacomblez, L,, Chacun, H,, Picard, V., Gimenez, F., Farinotti, R.,
Fernandez, C., 2006. Interactions between the dopamine agonist, bromocriptine
Dept of Pharmaceutics Page 196
C hap ter 7 References
and the efflux protein, P-glycopi'otein at tlie blocxi-braiii barrier iis the iriouse.
Eur. .1. Pharm. Sci, 2 7, 167..174.
Venna, R., Nehru, B,, 2009. Evffect of centroplieiioxine againsl rotenone-iiKliiced
oxidative stress in an anima! model of Parkinson’s disease. Neurochem. Int. 55,
369<VI5
Vila, A., Sancliez, A., Tobio, M., Caivo, P., Alonso, M.J., 2002. Design of
b io d e g ra d a b le p a r t ic le s fo r p ro te in deli very, .f. Comtrol. R e l . 78 (1 -3 ) , 15-24.
Vyas, T.K., Babbar, A.K., Sharma, R.K., Singh, S., Misra, A., 2006. Preliminary
Brain-targeting Studies on Intranasai mucoadhesivc microeiiiiiisions of
sumatriptan. AAPS Pharmscitech. 7, (I), !-8.
Vyas, T.K., Babbar, A.K., Siiarma, R.K., Singh, S., Misra, A,, 2006. Intranasai
miicoadhesive microemulsions of clonazepam: preliminary studies on brain
targeting. J. Pharm. Sci. 95 (3), 570-580.
Vyas, T.K., Shahiwala, A., Marathe, S., Misra, A., 2005. lutranasal drug delivery
for brain targeting, Curr. Drug. Deliv. 2, 165-475.
Wang, F., Jiang, X., Lu, VV., 2003. F’rofiles of methotrexate in blood and CSF
following intranasai and intravenous administration to rats. Int. J. Pharm. 263, 1-
7.
Wang, X., Chi, N., Tang, X., 2008. Preparation of estradiol chitosan nanoparticles
for improving nasal absorption and brain targeting 15ur. J. Phann. Biopharm. 70,
735-40.
Wang, Z.H., Wang. Z.Y., Sun, C.S., Wang, C.Y., Jiang, T. Y., Wang, S.L., 2010.
Triraethylated chitosan-conjugated PLGA naiioparticles for the delivery of drugs
to the brain. Biomaterials. 31(5), 908-915.
Wei, G., Wang, D., Lai, H., Parmentier, S., Wang, Q., F^anter, uS.S., Frey, W.H.,
Ying, W., 2007. Intranasai administration of a PARG inhibitor profoundly
decreases ischemic brain injury. Front. Biosci. 12, 4986-4996.
Wen, Z., Yan, Z., Hu, K., Pang, Z., Cheng, X., Guo, L., Zhang, Q., Ziang, X.,
Fang, L., Rai, R., 2011. Odorranalectin-conjugated nanoparticles; Preparation,
brain delivery and pharmacodynamic study on Parkinson's disease following
intranasai administration. J. Control. Release, 151, 131-138.
Dept of Pharmaceutics Page 197
C hapter 7 References r " z *- ' “ -L*zr ” - ^7 T" ” V
® Westin, U., Piras, E„ Jansson, B., Bergstrom, U., Dahlin, M., J3rittebo, E., Bjork,
E., 2005. T ra n s fe r o f m o rp h in e a lo n g tlie o l fa c to ry p a t l iw a y to tlie cerilj;al oervotis
sy s te m a f te r na sa l a d m in is t r a t io n to rodents. Eur. J. Pharrn. Sci. 24 (5 ) , 5 6 5 -5 7 3 .
® Wilson, B., Samanta, M.K., Santlii, K., Sarnpath. K., Ramasamy, IVL, Surcsli, B.,
2010. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug
tacrine. Nanomed; Nanotech. Bio. and Med. 6(1), 144-152.
s Winter, Y., Campenhausen, S.V., Popov, G., Reese, J.P., Gueicht, A., 2009. Costs
of iilness in a Russian cohort of patients with Parkinson’s disease.
Pharmacoeconomics. 27(7), 571-584.
© Wli, H., Hu, K., .hang, X., 2008. From nose to brain; understanding transport
capacity and transport rate of drugs. Expert: Opin. Drug Deliv. 5 (10), 1159-1168.
Wu, T.H., Yen, F.L., Lin, L.T., Tsai, T.R., Lin, C.C., Charn, T.M., 2008.
Preparation, physicochemical characterization, and antioxidant effects of
quercetin nanoparticles, hit. J. Pharm. 346(1-2), 160-168.
® WUj Y., Yang, W., Wang, C., Hu, ,1., Fu, S, 2005. Chitosan NPs as a novel
delivery system for ammonium giycyrrhizinate. int. J. Pharm. 295, 235~-245.
e Xu, Y., & Du, Y. 2003. Effect of molecular structure o f chitosan on protein
delivery properties of chitosan nanoparticles, hit, J. Pharrn. 250(1), 215 -226.
® Yin, Y., Chen, D., Qiao, M., Lu, Z., & Hu, H. 2006, Preparation and evahiation of
lectin-conjugated FLGA nanoparticles for ora! delivery of thyraopentin. J.
Control. Release, 116, 337-345.
Ying, W., Wei, G., Wang, D., Wang, Q., Tang, X., Shi, J,, Zhang, P., Lu, H.,
2007. Intranasal administration with NAI3+ profoundly decreases brain injury in a
rat model o f transient focal ischenu'a. Frorst. Biosci. 12, 2728-2734.
® Yu, S., Zhao, Y., Wu, F., Zhang, X., Lii, W,, Zhang, H., Zhang, Q., 2004. Nasal
insulin delivery in the chitosan solution; in vitro and in vivo studies, hit. J. Pharm.
281, 11-23.
® Yu, Y.P., Xit, Q.Q., Zhang, Q., 2005. Intranasal recombinant hiiman
erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett. 387, 5~
10.
Dept of Phariiiaceiitics PJige 198
« Zhang G, Sue L, Aiig P., 2008, Polyethyiene glyc()l-gr;ifted clrit:osan iianoparticies
nasai administration of insulin. J Pharm Sci, 85, 1-! L
e Zhang, L., Kosaraju, S. L., 2007. Kopolymeric delivery system for controlled
release of poiyphenolic antioxidaiits. Eiir. Polyrn J. 43(7), 2956-2966.
® Zhang, M., Olson, Ellenbogen, R.G., Veiseh, 0 ., Sun, C„ Gunn, J.W., 2007,
Chlorotoxin-labeled nanoparticle compositions and methods for targeting primary
brain tumors. US20070154965 A l,
® Zhang, Q., Jiang, X., Jiang, W., Lii, W., Su, L., Shi, Z., 2004. Preparation of
nimodipine loaded microemulsion ;for intranasal delivery and evaluation of the
targeting efficiency to brain. Int. J, Pharm. 275, 85-96,
® Zhang, Q., Shen, Z., Nagai, T ., 2001. Prolonged hypoglycaemic effect o f insufin-
loaded polybutylcyanoacrylate nanoparticles after piilrnonary administration to
normal rats. Int. J. Phami. 218, 75-80
e Zhou, S.B., Deng, X.M., Li, X.H., 2001. Investigation on a novel core-coated
microspheres protein delivery system. J. Control. Rel. 75, 27-36.
C hap ter 7 .References
Dept of Pharmaceutics Page 199